Navigation Links
Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function
Date:10/29/2007

Findings Presented at American Academy of Pediatrics National Conference &

Exhibition

SAN FRANCISCO and EAST NORRITON, Pa., Oct. 29 /PRNewswire/ -- Tengion, Inc., a leader in regenerative medicine, announced today that findings from a preclinical study being presented today at the American Academy of Pediatrics (AAP) National Conference and Exhibition demonstrate the ability of the Tengion Neo-Bladder Augment(TM) to restore bladder function in a well- established preclinical model of a bladder augmentation cystoplasty. These data were among the key findings that served as the basis for the company's 2006 Investigational New Drug (IND) submission with the U.S. Food and Drug Administration (FDA) for its autologous Neo-Bladder.

"We believe these data demonstrate that the Tengion Neo-Bladder Augment is safe, effective and enables the body to truly regenerate new cells and tissues. In this well-established pre-clinical model, only the Neo-Bladder Augment group was able to achieve functional recovery and a regenerative response that emulated the native bladder," said Tim Bertram, D.V.M., Ph.D., Senior Vice President, Science and Technology of Tengion. "These Tengion data join previous academic research of the autologous Neo-Bladder construct in pediatric patients -- published in The Lancet in April 2006 -- to create a compelling foundation for the promise and potential of Tengion's pipeline of regenerative medicine products. Tengion currently has two Phase 2 clinical trials ongoing evaluating the Neo-Bladder Augment: one in pediatric patients with neurogenic bladder due to spina bifida, and the other in adult patients with neurogenic bladder due to spinal cord injuries."

The purpose of the preclinical study described at AAP was to examine the structural and functional aspects of bladder regeneration in a well- established preclinical model. To do so, Tengion's Neo-Bladder Augment composed of a biodegradable scaffol
'/>"/>

SOURCE Tengion, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Reforming FDA: Focus on safety, let market judge efficacy
2. Chemical Stability of Disposables
3. Chemical Stability of the Brinkmann Bottletop Dispenser and the Brinkmann Bottletop Buret
4. Cell Proliferation and Viability Measurement
5. Rapid hit confirmation and early hERG liability testing using the IonWorks HT system
6. DNA Stability with Oragene
7. FluoroMax multiwavelength capability
8. Near IR capability of the FluoroLog
9. LIVE/DEAD Viability/Cytotoxicity Assay for Animal Cells Using the SpectraMax Gemini XS Fluorescence Microplate Reader (MaxLine Application Note #43)
10. The Affymetrix GeneChip Scanner 3000 New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
11. Promegas Multiplexed Cell Viability and Apoptosis Assays performed on the PHERAstar

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...employment grew by 29,000 jobs in October, and th...owth during the U.S. recession. However, clinics a...th systems are coming closer to having to actually...tors. , (Vocus) November ...ng in October despite the shedding of jobs in most...
(Date:11/24/2009)...re-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ),abiop...alizingnovelpainmanagementtherapies,announcedtoday...er,isscheduledtopresentatthe21stAnnualPiperJaffray...NewYorkPalaceHotelinNewYork,NewYork. ,, Mr.DiTo...eavailabletorespondtoquestionsduringthepresentatio...
(Date:11/24/2009)...tly approved the Promega PowerPlex 16 HS System fo...ng DNA records for the National DNA Index System. ... -- The FBI recently approved the Promega PowerPl...icipating in, or generating DNA records for, the N...ntains more than seven million profiles and has as...
(Date:11/24/2009)...rstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglo...edthatithassubmittedaMAAtotheEuropeanMedicinesAgen...enttherapyindevelopment,forthetreatmentofType1Gauc...elaglucerasealfathathasbeensubmitted,withprevious,...donaglobalsupplyshortageofthecurrentlyapprovedandm...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3
...ts for the Product,TopoTarget Successfully Buys Ba... the Global Rights for the Product ... Corporation, COPENHAGEN, April 22 , - Deal Cove..., a Total,of 5 Million TopoTarget Shares and a Com...all to be Held 2pm CET, TopoTarget A/S (OMX: TOPO...
...Ortho Evra is an adhesive,transdermal birth contro...lgestromin and 20 mcg of ethinyl estradiol into th...week for three weeks, and no patch is worn,during ...A in November,2001, and over 4 million women have ...tinues to be marketed aggressively to both consume...
.../PRNewswire-FirstCall/-- Pharmacyclics,Inc. (Nasda...aq staff,deficiency letter on April 17, 2008 indic...bid price for Pharmacyclics, common stock has clos...1.00 per share for continued,inclusion on The Nasd.... In,accordance with Marketplace Rule 4450(e)(2), ...
Other Biology Technology:TopoTarget Successfully Buys Back Full Control of Belinostat 2TopoTarget Successfully Buys Back Full Control of Belinostat 3TopoTarget Successfully Buys Back Full Control of Belinostat 4TopoTarget Successfully Buys Back Full Control of Belinostat 5TopoTarget Successfully Buys Back Full Control of Belinostat 6TopoTarget Successfully Buys Back Full Control of Belinostat 7Ortho Evra Patch Makers Settling Cases 2
(Date:11/25/2009)...may be used to boost resistance to, or slow, the d...Medicine researchers report in a study published i... , Parkinson,s disease is caused by a degenerati...known as the substantia nigra, which is responsibl...dopamine in late-stage Parkinson,s causes symptoms...
(Date:11/25/2009)...ps some 250 million liters of blood through the bo...the heart have to be extremely durable. The resear...air of the Department of Medicine III at Heidelber...atus), has discovered a protein that is responsibl... the sarcomere. In cooperation with other research...
(Date:11/24/2009)...standing how sounds associated with Navy sonar mig...ey hear it at all. , The same type of large indu...ct flaws in the space shuttle,s behemoth solid fue...e the giant head of a whale. The scans are providi...s hearing anatomy using a breakthrough method deve...
Breaking Biology News(10 mins):Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2Rocket science leads to new whale discovery 2Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 1Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 2Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 3Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 4Global Med Technologies 28R 29 Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product 14225 5Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer 5034 1Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer 5034 2Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer 5034 3Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer 5034 4Study reveals 2 3 of prostate cancer patients do not need treatment 58130 1Study reveals 2 3 of prostate cancer patients do not need treatment 58130 2
...out of the Ireland Cancer Center of University Hos... majority of triple negative breast cancers expres..., presented today at the San Antonio Breast Cancer...ine trial for patients with early stage triple neg... recurrence of this aggressive type of breast canc...
...lable in Spanish . , , The conditioning Works o...amount of vegetable species. The researchers of th...aged to grow in the laboratory two native bushy sp...able cover restoration. They will try to use them ... of Sierra Nevada . , The vegetable species of Si...
...ilable in French . , A novel x-ray technique al...me scale never reached before has been developed b...errer Institute (PSI) in Switzerland. Results of t...f EPFL,s laboratory of Ultrafast Spectroscopy in c...line December 11 in the journal Science . , This...
Other Biology News:Ireland Cancer Center researcher finds most triple-negative breast cancers express muc-1 target 2An essay proves that vegetation could recover in the ski resort of Sierra Nevada 2Molecules in the spotlight 2
Anti-Taste Receptor 2 (TR2) Polyclonal Antibody, Unconjugated from CHEMICON
Anti-Latanoprost (EIA Antiserum) Antibody, Unconjugated from Cayman Chemical
Anti-SEK1 / MKK4, phospho (Thr261) Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-BACE/Asp2 (CT) Polyclonal Antibody, Unconjugated from Assay Designs/Stressgen Bioreagents
Biology Products: